INT9677

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1985
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 46
Total Number 47
Disease Relevance 23.32
Pain Relevance 3.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (GH1) extracellular region (GH1)
Anatomy Link Frequency
adipose tissue 4
plasma 2
liver 2
fat 2
pituitary 2
GH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 182 99.84 Very High Very High Very High
antidepressant 3 99.76 Very High Very High Very High
agonist 163 99.18 Very High Very High Very High
Dopamine 171 99.02 Very High Very High Very High
depression 10 98.40 Very High Very High Very High
tolerance 134 98.16 Very High Very High Very High
imagery 114 95.96 Very High Very High Very High
Clonidine 27 91.72 High High
carpal tunnel syndrome 25 88.72 High High
antagonist 25 82.64 Quite High
Disease Link Frequency Relevance Heat
Obesity 242 99.90 Very High Very High Very High
Acromegaly 488 99.52 Very High Very High Very High
Disease 307 99.52 Very High Very High Very High
Diabetes Mellitus-type I 1 99.52 Very High Very High Very High
Growth Hormone Deficiency 61 99.26 Very High Very High Very High
Cancer 419 99.12 Very High Very High Very High
Chronic Renal Failure 213 98.84 Very High Very High Very High
Reprotox - General 1 28 98.76 Very High Very High Very High
Atherosclerosis 24 98.52 Very High Very High Very High
Impaired Glucose Tolerance 135 98.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nevertheless, our results were in agreement with other studies, and the fact that individual GH profiles at 18–24 h on Days 7–8 were relatively flat compared to those obtained on Day 1 suggests that GH administration did suppress endogenous GH production to some extent.
Negative_regulation (suppress) of Gene_expression (production) of GH
1) Confidence 0.48 Published 2007 Journal Clinical Endocrinology Section Body Doc Link PMC2366021 Disease Relevance 0.31 Pain Relevance 0
Previous investigations of patients with chronic renal failure have also observed reduced concentration of GHBP,24,38 which may indicate decreased expression of the GH receptor in target tissues, and hence diminished responsiveness to GH in renal failure.
Negative_regulation (decreased) of Gene_expression (expression) of GH associated with chronic renal failure and renal failure
2) Confidence 0.48 Published 2007 Journal Clinical Endocrinology Section Body Doc Link PMC2366021 Disease Relevance 0.51 Pain Relevance 0
Individual GH profiles (not shown) for the period 18–24 h on Days 7–8 were relatively flat compared to the peaks obtained on Day 1 for all subjects (particularly noticeable for the patient group) (Fig. 2, inserts), demonstrating that administration of rhGH appeared to suppress endogenous GH production.
Negative_regulation (suppress) of Gene_expression (production) of GH
3) Confidence 0.48 Published 2007 Journal Clinical Endocrinology Section Body Doc Link PMC2366021 Disease Relevance 0.08 Pain Relevance 0
A significant decrease in plasma ANP (pmol/L) after GH administration was observed: 2.28 +/- 0.54 (GH), 3.16 +/- 0.53 (placebo) P less than 0.01.
Negative_regulation (decrease) of Gene_expression (administration) of GH in plasma
4) Confidence 0.41 Published 1991 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 1826008 Disease Relevance 0.40 Pain Relevance 0.08
A PK study of intravenous GH administration found a strong positive correlation between baseline GHBP concentration and MCR at physiological GH concentrations.39 In addition, the reduced GH elimination rate observed in GH-deficient patients in another study was explained by lower levels of GHBP, possibly reflecting a reduced GH receptor density and hence clearance.40
Negative_regulation (intravenous) of Gene_expression (administration) of GH
5) Confidence 0.35 Published 2007 Journal Clinical Endocrinology Section Body Doc Link PMC2366021 Disease Relevance 0.55 Pain Relevance 0
The rhGH dose chosen was the highest dose employed in a previous trial of subcutaneous GH treatment in 139 patients with ESRD (37 dosed with 50 µg/kg bw/day, as in this trial), where GH treatment was found to be safe.21
Negative_regulation (safe.21) of Gene_expression (treatment) of GH associated with chronic renal failure
6) Confidence 0.35 Published 2007 Journal Clinical Endocrinology Section Body Doc Link PMC2366021 Disease Relevance 0.77 Pain Relevance 0.08
Treatment is aimed at correcting (or preventing) tumor compression by excising the disease-causing lesion, and at reducing GH and IGF-I levels to normal values.
Negative_regulation (reducing) of Gene_expression (levels) of GH associated with cancer and disease
7) Confidence 0.34 Published 2008 Journal Orphanet J Rare Dis Section Abstract Doc Link PMC2459162 Disease Relevance 1.25 Pain Relevance 0.27
Nevertheless, these levels normalize in only 40% to 70% of cases [66-69], depending on the size of the tumor (microadenomas are more amenable to cure), preoperative GH concentrations (the success rate is higher when GH concentrations are low, i.e. <10 ?
Negative_regulation (preoperative) of Gene_expression (concentrations) of GH associated with cancer
8) Confidence 0.34 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2459162 Disease Relevance 0.79 Pain Relevance 0
Her GH levels were substantially reduced after initiating the treatment, but they did not drop to the target of <2.5 ng/ml at any time during the 17 months of treatment (Table 1).
Negative_regulation (reduced) of Gene_expression (levels) of GH
9) Confidence 0.33 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2845144 Disease Relevance 0.56 Pain Relevance 0.03
Her GH levels were 12 ng/ml and were not suppressed by a standard oral glucose load.
Neg (not) Negative_regulation (suppressed) of Gene_expression (levels) of GH
10) Confidence 0.33 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2845144 Disease Relevance 0.96 Pain Relevance 0.23
In April 2008, (approximately 14 months after initiating treatment), her IGF-1 and GH levels had decreased to within, or close to, the normal range (Table 1), which was at 332 ng/ml for IGF-1 and <2.5 ng/ml for GH.
Negative_regulation (decreased) of Gene_expression (levels) of GH
11) Confidence 0.33 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2845144 Disease Relevance 0.89 Pain Relevance 0.21
The mid and late trimesters decrease in GH-BP levels in spite of increasing sex steroids concentrations, may be attributed to the decreasing hCG concentrations, and/or to the increasing secretion of placental lactogen (PL) and placental GH with the advancing gestation.
Negative_regulation (decrease) of Gene_expression (levels) of GH-BP
12) Confidence 0.31 Published 1992 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 1430084 Disease Relevance 0.13 Pain Relevance 0.05
A few patients with clear clinical signs of acromegaly and a high IGF-I level have a GH nadir of <1 ?
Negative_regulation (have) of Gene_expression (nadir) of GH associated with acromegaly
13) Confidence 0.29 Published 2008 Journal Orphanet J Rare Dis Section Body Doc Link PMC2459162 Disease Relevance 0.47 Pain Relevance 0
The corresponding percentage declines in visceral fat in the GH and GH + PIO groups were 13.1% and 16.6%, respectively, indicating the lipolytic effect of GH on this adipose tissue depot.
Negative_regulation (declines) of Gene_expression (groups) of GH in adipose tissue associated with obesity
14) Confidence 0.29 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1865086 Disease Relevance 0.64 Pain Relevance 0.04
Decreases in growth hormone (GH) and insulin-like growth factor-I, estrogen deficiency in women, diminished testosterone in men, and loss of lean body mass, increased fat, and other changes consistent with hormone deficiencies occur during aging.
Negative_regulation (deficiency) of in fat Gene_expression (Decreases) of GH in body associated with aging
15) Confidence 0.27 Published 2004 Journal J. Gerontol. A Biol. Sci. Med. Sci. Section Abstract Doc Link 15304529 Disease Relevance 0.68 Pain Relevance 0.13
Decreases in growth hormone (GH) and insulin-like growth factor-I, estrogen deficiency in women, diminished testosterone in men, and loss of lean body mass, increased fat, and other changes consistent with hormone deficiencies occur during aging.
Negative_regulation (loss) of in fat Gene_expression (Decreases) of GH in body associated with aging
16) Confidence 0.27 Published 2004 Journal J. Gerontol. A Biol. Sci. Med. Sci. Section Abstract Doc Link 15304529 Disease Relevance 0.77 Pain Relevance 0.14
Exogenous growth hormone (hGH) administration in humans attenuates the endogenous growth hormone (GH) response to some pharmacological stimuli; in particular, pretreatment with hGH completely blocks the serum GH response to growth hormone-releasing hormone.
Negative_regulation (attenuates) of Gene_expression (administration) of hGH
17) Confidence 0.25 Published 1996 Journal Eur. J. Endocrinol. Section Abstract Doc Link 8590960 Disease Relevance 0 Pain Relevance 0.15
The corresponding percentage reductions for SSPG in the PIO and GH + PIO groups were similar: 21.4% in the PIO group and 19.6% in the GH + PIO group.
Negative_regulation (reductions) of Gene_expression (groups) of GH
18) Confidence 0.25 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1865086 Disease Relevance 0.55 Pain Relevance 0.04
The corresponding percentage declines in visceral fat in the GH and GH + PIO groups were 13.1% and 16.6%, respectively, indicating the lipolytic effect of GH on this adipose tissue depot.
Negative_regulation (declines) of Gene_expression (groups) of GH in adipose tissue associated with obesity
19) Confidence 0.25 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1865086 Disease Relevance 0.64 Pain Relevance 0.04
A similar decline in VAT was seen in the GH + PIO group versus placebo, with a mean difference of ?
Negative_regulation (seen) of Gene_expression (group) of GH associated with obesity
20) Confidence 0.25 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1865086 Disease Relevance 0.58 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox